Wakelee, Heather A.
Gettinger, Scott
Engelman, Jeffrey
Jänne, Pasi A.
West, Howard
Subramaniam, Deepa S.
Leach, Joseph
Wax, Michael
Yaron, Yifah
Miles, Dale R.
Lara, Primo N. Jr.
Funding for this research was provided by:
Exelixis
National Center for Research Resources (UL1 RR025744)
Article History
Received: 13 February 2017
Accepted: 9 March 2017
First Online: 28 March 2017
Compliance with ethical standards
:
: H.A. Wakelee received consultant fees and honoraria from Peregrine, Acea, Pfizer, Helsinn, Genentech (uncompensated), and received research/grants from Clovis, Exelixis, AstraZeneca/MedImmune, Genentech/Roche, BMS, Gilead, Novartis, Xcovery, Pfizer, Celgene, Pharmacyclics, and Lilly. S. Gettinger, D.S. Subramaniam, J. Leach, and M. Wax have no conflicts of interest to report. J. Engelman is an employee of Novartis and has received equity in Novartis. P. A. Jänne has received consulting fees for drug development from AstraZeneca, Boehringer Ingleheim, Pfizer, Roche, Genentech, ARIAD Pharmaceuticals, Ignyta, and LOXO Oncology; sponsored research funding from AstraZeneca, PUMA, and Daiichi-Sankyo; and post-marketing royalties on DFC-owned intellectual property on EGFR mutations licensed to Lab Corp. H. West received consultant fees and honoraria from AstraZeneca, Boehringer Ingleheim, Genentech/Roche, and TrovaGene. Y. Yaron is an employee of Exelixis and owns stock and stock options in Exelixis. D. R. Miles was an employee of Exelixis and received stock from Exelixis when the study was underway. P.N. Lara received consultant fees from Exelixis.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.